GHK-Cu has a small human signal for eyebrow growth, but it has not been shown to regrow thinning scalp hair. A 2026 study tested a topical GHK-Cu serum on 18 people’s eyebrows for 12 weeks. It did not test scalp hair loss, injections, or a dry research vial. That distinction matters when a post says a “copper peptide” helped someone’s hair.
Why are people asking about GHK-Cu and hair?
GHK-Cu is a copper-bound peptide discussed in skin and tissue research. Hair-growth claims spread easily because laboratory studies of hair follicles, small studies of cosmetic products, and personal reports often get grouped together. Those sources answer different questions. PeptideWhy’s GHK-Cu profile gives broader context about the compound and the limits of research-vial claims.
What did the 2026 human study find?
Researchers assigned one eyebrow of each of 18 adults to a topical 2% GHK-Cu serum and the other to a comparison serum. The study was described as randomized and double-blind. After 12 weeks, the authors reported better eyebrow hair counts, hair diameter, photo ratings, and participant satisfaction on the GHK-Cu side. They reported no serious adverse effects or allergic reactions during that short study. Read the original report.
This is a useful early result, with narrow limits: 18 participants, one product, eyebrows rather than the scalp, and 12 weeks of observation. It cannot tell us whether GHK-Cu treats male or female pattern hair loss, whether a different formulation works, what happens over years, or whether injecting a research vial is safe or effective. The studied percentage and schedule describe that trial, not a general use recommendation.
Why do older “hair peptide” studies get misread?
A frequently cited 2007 paper tested AHK-Cu, a different copper peptide, on human hair follicles outside the body and on cultured cells. The follicles elongated under those laboratory conditions. The paper did not test GHK-Cu on people with hair loss. “Human follicles” in a dish does not mean a clinical trial in humans. Read the AHK-Cu study.
A 2016 trial followed 45 men with pattern hair loss using a product combining 5-aminolevulinic acid and GHK peptide. One comparison showed a larger hair-count change than placebo, but the product contained more than GHK and was not a test of GHK-Cu alone. The study did not find a significant difference in hair length or thickness among its three groups at six months. Read the combination-product study.
What can someone conclude for scalp hair loss?
At present, the eyebrow result is encouraging but does not establish scalp regrowth. The AHK-Cu experiment uses another molecule; the 2016 study uses a combination. Personal before-and-after photos cannot isolate GHK-Cu from other products, normal hair-cycle changes, or differences in lighting and styling. No study above validates an injectable research vial as a hair-loss treatment.
Hair thinning also has different causes, including hereditary pattern loss, shedding after illness, and some medical conditions. The American Academy of Dermatology says finding the cause is the starting point for choosing care. A dermatologist can help if the loss is new, rapid, patchy, or progressing.
Three questions to ask when reading the next claim
- Which molecule? GHK-Cu, AHK-Cu, and a GHK combination product are not interchangeable.
- Where was it tested? Cells, isolated follicles, eyebrows, and a living person’s scalp are different settings.
- Which form and outcome? A topical cosmetic serum and an injectable research vial are different products; an eyebrow hair count is not proof of scalp regrowth.
Sources checked October 15, 2026. This article explains research findings and does not recommend using a research-only product on or in a person.